Microcirculation in Hypertension: A Therapeutic Target to Prevent Cardiovascular Disease?

Damiano Rizzoni1, Claudia Agabiti-Rosei1,2, Gianluca E M Boari3

  • 1Department of Clinical and Experimental Sciences, University of Brescia, 25121 Brescia, Italy.

PubMed

Insights

Hypertension causes vascular remodeling, increasing the media-to-lumen ratio (MLR) and impairing blood flow. These microvascular changes are linked to organ damage and cardiovascular events, but may improve with treatment.

Area of Science:

  • Cardiovascular Research
  • Nephrology
  • Ophthalmology

Background:

  • Arterial hypertension is a global health issue, significantly increasing risks for cardiovascular and cerebrovascular events, kidney disease, and eye conditions.
  • Established hypertension induces chronic vasoconstriction and vascular remodeling in small arteries, characterized by decreased lumen diameter and thickened arterial walls, leading to an increased media-to-lumen ratio (MLR).
  • This vascular remodeling, initially assessed via micromyography, is now understood as a generalized phenomenon with significant prognostic implications.

Purpose of the Study:

  • To review the relationship between structural microvascular alterations in hypertension and hypertension-mediated organ damage.
  • To explore the potential for antihypertensive treatments to improve these microvascular changes.
  • To highlight the prognostic relevance of microvascular remodeling in cardiovascular and cerebrovascular events.

Main Methods:

  • Micromyography for assessing structural alterations in small resistance arteries (gold-standard).
  • Emerging non-invasive techniques like scanning laser Doppler flowmetry and adaptive optics for evaluating wall-to-lumen ratio (WLR) in retinal arterioles.
  • Analysis of studies reporting capillary network rarefaction in hypertensive patients.

Main Results:

  • Increased MLR/WLR in small arteries impairs organ blood flow reserve, contributing to hypertensive disease progression and organ damage.
  • Retinal microvascular WLR has demonstrated prognostic value for cardiovascular and cerebrovascular events.
  • Capillary rarefaction in hypertension may reduce tissue oxygen delivery, potentially initiating organ damage and dysfunction.

Conclusions:

  • Microvascular alterations, including remodeling and rarefaction, are early indicators of hypertension-mediated organ damage.
  • These microvascular changes play a critical role in the development and progression of hypertension-related complications.
  • Monitoring and improving microvascular structure through antihypertensive treatment holds promise for better patient outcomes.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
15
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
14
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
27
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
11
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
566